RxDoctor Payments Data

Gary Korff, MD

Family Medicine · Carlsbad, CANPI 1063585495

Payments from drug & device makers

$248,322in general payments, 2019–2025

Across 77 payments — averaging $3224.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$163K
  • AstraZeneca$33K
  • Astrazeneca UK Limited$29K
  • Abbott$18K
  • Novo Nordisk AS$5K
  • GSK$103
  • plus $361 from 14 others

What the payments were for

  • Food & beverage$545100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$248,322 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$63,944
Medicare patients
158
Services billed
964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$86,072
OzempicSemaglutide69$84,132
JardianceEmpagliflozin24$34,259
RybelsusSemaglutide23$29,848
MounjaroTirzepatide23$26,765
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$23,816
ShingrixVaricella-Zoster Ge/As01b/Pf100$22,391
XareltoRivaroxaban20$14,857
FarxigaDapagliflozin Propanediol13$12,754
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$9,491
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$8,871
TradjentaLinagliptin11$5,647
SymbicortBudesonide/Formoterol Fumarate13$4,910
Atorvastatin Calcium449$4,770
Amlodipine-ValsartanAmlodipine Besylate/Valsartan75$3,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$38$113,98092 claims
PfizerEliquis$75$86,07274 claims
GSKTrelegy Ellipta, Shingrix, Anoro Ellipta$103$55,699144 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta$11$48,77853 claims
Lilly USA, LLCMounjaro$20$26,76523 claims
AstraZenecaFarxiga, Symbicort$33,243$17,66526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Carlsbad

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →